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ABSTRACT
Polyadenylation of mRNA in human mitochondria
is crucial for gene expression and perturbation
of poly(A) tail length has been linked to a human
neurodegenerative disease. Here we show that
20-phosphodiesterase (20-PDE), (hereafter PDE12),
is a mitochondrial protein that specifically removes
poly(A) extensions from mitochondrial mRNAs
both in vitro and in mitochondria of cultured cells.
In eukaryotes, poly(A) tails generally stabilize
mature mRNAs, whereas in bacteria they increase
mRNA turnover. In human mitochondria, the
effects of increased PDE12 expression were tran-
script dependent. An excess of PDE12 led to an
increase in the level of three mt-mRNAs (ND1, ND2
and CytB) and two (CO1 and CO2) were less
abundant than in mitochondria of control cells and
there was no appreciable effect on the steady-state
level of the remainder of the mitochondrial tran-
scripts. The alterations in poly(A) tail length accom-
panying elevated PDE12 expression were
associated with severe inhibition of mitochondrial
protein synthesis, and consequently respiratory in-
competence. Therefore, we propose that mRNA
poly(A) tails are important in regulating protein syn-
thesis in human mitochondria, as it is the case for
nuclear-encoded eukaryotic mRNA.
INTRODUCTION
Mitochondria are vital organelles as they provide energy
to the cell via the process of oxidative phosphorylation
(OXPHOS). The 16.6kb circular human mitochondrial
genome (mtDNA) encodes 2 rRNAs, 22 tRNAs and
13 essential protein components of the OXPHOS
complexes (1). The remaining proteins of the mitochon-
drial proteome (>99%), including all factors necessary for
the maintenance and expression of mtDNA, are encoded
by the nucleus. Both mtDNA strands (termed H and L)
are almost entirely transcribed from the promoters located
in the control non-coding region. Resulting polycistronic
RNA molecules are then processed to produce mRNAs,
rRNAs and tRNAs (2). Human mitochondrial mRNAs
(mt-mRNAs) released by this processing do not contain
introns and lack any cap or modiﬁcation at the 50-end;
however, they do have  50 adenosine residues added at
the 30-terminus by a dedicated mitochondrial poly(A)
polymerase (3,4). Seven of the 13 open reading frames
(ORFs) require polyadenylation to create a translation
stop codon (5).
Regulation of human mitochondrial RNA (mt-RNA)
surveillance and turnover has not been well characterized
thus far (6,7); also the regulatory mechanisms that control
mitochondrial translation are poorly understood (8).
In many systems, RNA polyadenylation plays an import-
ant role both in controlling mRNA stability and in
modulating translation (9). The human mitochondrial
poly(A) polymerase (hmtPAP) responsible for the synthe-
sis of the mitochondrial poly(A) extensions has been
identiﬁed (3,4), however, inactivation of this enzyme did
not yield a clear answer to the role of poly(A) extensions
in the stability of mt-RNAs. The siRNA-mediated
knockdown of hmtPAP led to shortening of mitochon-
drial 30-poly(A) extensions, but this either did not affect
the stability (3) or resulted in decreased steady-state levels
of some mt-mRNAs (4,10). Furthermore, analysis of the
ATP6/8 mt-mRNA (RNA14) harbouring a microdeletion
in the translation stop codon in a patient-derived cell line
showed that this message has shortened poly(A) tails and
is less stable, consistent with the poly(A) tail stabilizing
the ATP6/8 mRNA (11). Another approach based
upon mitochondrial targeting of a poly(A)-speciﬁc 30-
exoribonuclease PARN led to efﬁcient RNA
deadenylation; however, this had a variable effect on
mt-mRNA steady-state levels, increasing or decreasing
particular mRNAs with no effect on others (12).
Another previous study showed that a fraction of the
mt-RNA is truncated and internally polyadenylated, con-
sistent with the possibility that a poly(A)-dependent deg-
radation pathway exists in human mitochondria (13).
Also, oligoadenylation at the 30-termini has been sug-
gested to precede the addition of long poly(A) tails,
(14,15), but to date no enzyme responsible for the
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analogy with the role of RNA polyadenylation in the
cytosol of eukaryotes, poly(A) tails may also play a role
in modulating mitochondrial translation. However, this
potential function has received very little attention thus
far (12).
Deadenylase enzymes ensure changes of the lengths
of mRNA poly(A) in order to regulate mRNA stability
and therefore protein production. All known human
deadenylases belong to two enzyme families classiﬁed on
the basis of conserved nuclease motifs (16): (i) the DEDD
family, e.g. POP2, PARN and PAN2 deadenylases and (ii)
the ribonucleases of the exonuclease/endonuclease/phos-
phatase (EEP) family, e.g. CCR4 (CNOT6), Nocturnin
and ANGEL (16). All human deadenylases characterized
thus far have been localized either to the cytosol or the
nucleus (or found to shuttle between these two compart-
ments). Therefore, the mechanism of regulation of mRNA
poly(A) tail length in mitochondria was not known.
We studied PDE12 because it shares sequence hom-
ology with known RNA deadenylases and in silico
analysis predicted its a mitochondrial localization.
PDE12 is an exoribonuclease with a preference for
homo-adenine oligonucleotides, and removes poly(A) tail
extensions from mt-mRNAs in vitro and in mitochondria
of cells in culture. Deadenylation altered the steady-state
level of some, but not other, mitochondrial mRNAs,
which may explain earlier contradictory results of the
effect of mitochondrial poly(A) tails on controlling
mt-mRNA stability. We also show that deadenylation of
mt-mRNA led to a marked inhibition of mitochondrial




In order to construct the pcDNA5-PDE12.Strep2.Flag
plasmid used to generate an inducible Flp-In T-Rex
TM
human embryonic kidney 293T (HEK293T) cell line,
two oligonucleotides encoding an AgeI restriction site,
Flag and Strep2 epitope tags were annealed and cloned
into XbaI (50) and ApaI (30) restriction sites of pcDNA5/
FRT/TO (Invitrogen). The resulting plasmid was named
pcDNA5-FST2. The cDNA-encoding PDE12 (IMAGE
clone: 4823249) was then modiﬁed by PCR to introduce
unique KpnI (50) and AgeI (30) sites and the resulting
fragment was cloned into pcDNA5-FST2 using the
above restriction sites. The E351A catalytic mutant was
generated using PCR-based mutagenesis and the resulting
cDNA was cloned into pcDNA5-FST2 as above. For
transfection of mammalian cells plasmid, DNA was
puriﬁed using a Qiaﬁlter MidiPrep Kit (Qiagen).
Maintenance, transfection and growth analysis of
mammalian cell lines
Human 143B osteosarcoma (HOS) cells that are routinely
used by us for immunoﬂuorescence localization of mito-
chondrial proteins were cultured in Dulbecco’s Modiﬁed
Eagle Medium (DMEM) containing 2mM L-glutamine
(Invitrogen) with 10% FBS (PAA Laboratories). For
immunoﬂuorescence experiments, HOS cells were
electroporated with pcDNA5-PDE12.Strep2.Flag using
Cell Line Nucleofector (Lonza) and buffer kit V (Lonza)
applying programme I-13.
The Flp-In T-Rex
TM HEK293T cell line (Invitrogen),
which allows for the generation of stable, doxycycline-
inducible expression of transgenes by FLP recombinase-
mediated integration was used to express PDE12
.Strep2.Flag and the E351A catalytic mutant. HEK293T
cells were grown in DMEM containing 2mM L-glutamine
(Invitrogen), 10% tetracycline free FCS (Autogen
Bioclear) and supplemented with 100mg/ml Zeocin
(Invivogen) and 15mg/ml Blasticidin (Invivogen).
Twenty-four hours prior to transfection cells were split to
10cm plates, grown to 80–90% conﬂuence and transfected
using Cell Line Nucleofector (Lonza), buffer kit V (Lonza)
applying programme A-23. Twenty-four hours after trans-
fection, the selective antibiotics hygromycin (100mg/ml,
Invivogen) and blasticidin (15mg/ml) were added and the
selective medium was replaced every 3–4 days. For growth
on respiratory substrates, the medium contained
glucose-free DMEM (Gibco), 0.9mg/ml galactose, 1mM
sodium pyruvate, 10% (v/v) FCS and 2mM L-glutamine.
For growth measurements cells were plated in six-well
plates and grown with 50ng/ml of doxycycline in galact-
ose or glucose containing medium. Cells were harvested
from replicate plates on alternate days and total cell
counts made using a Neubauer haemocytometer.
Immunodetection of proteins
The immunoﬂuorescence localization of proteins in
ﬁxed HOS cells were performed as described previously
(17). The following antibodies were used: anti-Flag IgG
(Sigma, 1:200), FITC-conjugated anti-mouse IgG (Sigma,
1:200). Immunoﬂuorescence images were captured using a
Zeiss LSM 510 META confocal microscope.
For immunoblot analysis, equal amounts of proteins
corresponding to total cell lysates or protein fractions
were subjected to SDS–PAGE, semi-dry transferred to
nitrocellulose membranes, blocked in 5% non-fat milk
(Marvel) in PBS for 1h and incubated with speciﬁc
primary antibodies in 5% non-fat milk in PBS for 1h
or overnight. The blots were further incubated with
HRP-conjugated secondary antibodies in 5% non-fat
milk in PBS for 1h and visualized using ECL
+
(Amersham).
The primary antibodies used were: rabbit anti-PDE12
(Abcam, 1:1000), mouse anti-FLAG IgG (Sigma, 1:5000),
rabbit anti-b-actin IgG (1:7000, Sigma), mouse anti-CO2
IgG (1:5000, Abcam), rabbit anti-TFAM IgG (kindly
donated by Professor Rudolf Wiesner, University of
Cologne, 1:4000), mouse anti-GAPDH IgG (Abcam,
1:10000), mouse anti-Complex I subunit NDUFB8
(MitoSciences, 1:2000), mouse anti-Complex II subunit
30kDa (MitoSciences, 1:2000), mouse anti-Complex
III subunit Core 2 (MitoSciences, 1:2000), rabbit
anti-VDAC-1 IgG (Abcam, 1:5000), mouse anti-DAP3
IgG (Abcam, 1:1000) and goat anti-MRPL3 (Abcam,
1:1000).
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(Promega, 1:2000), anti-mouse IgG-HRP (Promega,
1:2000) and anti-goat IgG-HRP (Sigma, 1:1000).
Protein puriﬁcation
Mitochondria derived from HEK293T cells expressing
PDE12.Strep2.Flag or the E351A catalytic mutant were
isolated as described previously (18) and resuspended to
8 mg protein/ml in 40 mM HEPES (pH7.6), 10mM
EDTA, 4mM DTT, 0.4mM PMSF, 300mM NaCl and
protease inhibitor cocktail (Roche). Next, the
mitochondria were lysed by mixing with an equal
volume of 0.8% dodecylmaltoside (DDM) in water, on a
roller at 4 C for 30min. The lysate was centrifuged at
1600gmax for 10min to remove insoluble debris and the
supernatant was loaded onto a gravity ﬂow Strep-Tactin
column (IBA) and the ﬂow-through re-loaded twice. The
column was washed sequentially with ﬁve column volumes
(CV) of washing buffer containing 20mM HEPES
(pH 7.6), 1mM EDTA, 2mM DTT, 0.2mM PMSF,
150mM NaCl, 0.05% DDM, protease inhibitors
(Roche) and eluted six times with 0.5CV elution buffer
(washing buffer plus 10mM desthiobiotin). Peak fractions
containing PDE12.Strep2.Flag were concentrated using
Vivaspin 2 Centrifugal Concentrators (Sartorius stedim),
supplemented with glycerol to 20% and stored at  80 C.
In order to assess the purity and identity of the
Strep-Tactin puriﬁed proteins, the preparations were
separated by SDS–PAGE, Coomassie stained and
protein bands were excised from gels and identiﬁed by
mass spectrometry.
Nuclease assays
The reaction substrates were prepared by: (i) 50-end-
labelling of RNA or DNA oligonucleotides with T4
Polynucleotide Kinase (New England Biolabs) according
to the manufacturer’s instructions; (ii) in vitro run off tran-
scription of PCR-generated templates [encompassing T7
promoter (50) and 50 adenine nucleotides where appropri-
ate (30)] using MAXIscript T7 Kit (Ambion) in the
presence of 0.825mM a-
32P UTP (3000Ci/mmol, Perkin
Elmer] according to the manufacturer’s instructions; or
(iii) ligating the 30-end of RNA oligonuclotides with radio-
active pCp (PerkinElmer) using T4 RNA ligase (New
England Biolabs).
The reaction mixture of 20ml containing 5pmoles of the
substrate, 50mM HEPES (pH8.0), 10mM MgCl2,
0.5mM DTT, 100mg/ml BSA, 4U of RNasin (Promega)
and 8.5pmols of PDE12 or E351A catalytic mutant were
incubated at 37 C for the indicated time. The samples
were analysed on 5–10% urea polyacrylamide gels in 1 
glycerol tolerant buffer (GTB) containing 90mM Tris–
base, 30mM Taurine and 0.5mM EDTA.
Analysis of mitochondrial poly(A) by circular reverse
transcription–PCR assay
Circular reverse transcription PCR (cRT–PCR) labelling
and sequencing were used to determine both 50- and
30-ends of mt-RNA as described in Tomecki et al. (3)
with minor modiEcations. Brieﬂy, 2.5mg of total RNA
was circularized with T4 RNA ligase (New England
Biolabs) in the presence of DNAse I (Roche) followed
by phenol–chloroform extraction and ethanol precipi-
tation. Reverse transcription was carried out using
Omniscript Reverse Transcriptase (Qiagen) with a
gene-speciﬁc reverse primer, generally termed R1. Newly
synthesized cDNA was used as a template for a PCR
reaction, primed with R1 primer and a forward primer,
F1. The region ampliﬁed contained the junction of the 50-
and 30-extremities. A second round of PCR with the
nested reverse primer, R2, and forward primer, F2, was
applied. Products were cloned into pCRII-TOPO vector
(TOPO TA Cloning Kit, Invitrogen) and sequenced.











RNA isolation and northern blotting
Total RNA from HEK293T cells was isolated using Trizol
(Invitrogen) according to the manufacturer’s instructions.
For northern blots, RNA was resolved on 1% agarose
gels containing 0.7M formaldehyde in 1  MOPS buffer,
transferred to a nylon membrane in 2  SSC and
hybridized with radioactively labelled PCR fragments cor-
responding to appropriate regions of mtDNA.
Measurement of mitochondrial respiration and membrane
potential
HEK293T cells expressing PDE12 were seeded at
3 10
4cells/well in 200ml growth medium in XF 24-well
cell culture microplates (Seahorse Bioscience) and
incubated at 37 Ci n5 %C O 2 for 36–40h. One hour
before the assay growth medium was removed and
replaced with assay medium (low buffered DMEM,
10mM L-glutamine, 1mM sodium pyruvate, 2mM
glucose), with one rinse with assay medium, and left to
stabilize in a 37 C non-CO2 incubator. Analysis was per-
formed in quadruplicates using XF24 Extracellular Flux
Analyzer (Seahorse Bioscience). The wells containing cells
were sequentially injected with 20mM 2-deoxyglucose
(2-DG) to inhibit glycolysis, 100nM oligomycin to
inhibit ATP synthase, 500–1000nM carbonylcyanide-4-
triﬂuorometho-xyphenylhydrazone (FCCP) to uncouple
the respiratory chain and 200nM rotenone to inhibit
complex I. Oxygen consumption rate (OCR) was
measured for each well every 5min before and after each
injection. Test compounds: 2-DG, oligomycin, FCCP and
rotenone were obtained from Sigma.
7752 Nucleic Acids Research, 2011,Vol.39, No. 17For membrane potential measurements, 4 10
5 cells
were stained with 100nM tetramethylrhodamine ethyl
ester (TMRE) (Invitrogen) in PBS for 1h at 37 C,
trypsinized, resuspended in PBS and analysed by BD
LSRII ﬂow cytometer. Debris and apoptotic cells were
excluded from the analyses using Forward and Side
Scatter gate. Acquired data were analysed by FlowJo
software (Tree Star, Inc.). Experiments were performed
for three independent transgene inductions with triplicate
measurements based on 20000 events.
35S-methionine metabolic labelling of mitochondrial
proteins
Stably transfected HEK293T cells expressing PDE12 (or
E351A) were induced with doxycycline (50ng/ml) for 2 or
4 days prior to
35S labelling. Growth medium was replaced
with methionine/cysteine-free DMEM (Sigma) supple-
mented with 2mM L-glutamine, 48mg/ml cysteine and
50mg/ml uridine. The cells were incubated for 2 10min
in this medium and then transfered into fresh methionine/
cysteine-free DMEM medium containing 10% (v/v)
dialysed FCS and emetine dihydrochloride (100mg/ml).
Cells were incubated for 10min before addition of
120mCi/ml of [
35S]-methionine. Labelling was performed
for 15min and the cells were washed twice with standard
growth medium. Protein samples (30mg) were separated by
4–12% SDS–PAGE and products visualized and quantiﬁed
with a PhosphorImager system with ImageQuant software
(Molecular Dynamics, GE Healthcare).
Analysis of mitochondrial ribosome proﬁle on density
gradients
Total cell lysates (0.7mg) were loaded on a linear sucrose
gradient [2ml 10–30% (v/v)] in 50mM Tris–HCl (pH7.2),
10mM Mg(OAc)2,8 0 m MN H 4Cl, 0.1M KCl, 1mM
PMSF and centrifuged for 2h 15min at 100000gmax at
4 C (39000rpm, Beckman Coulter TLS-55 rotor). Twenty
fractions (100ml) were collected and 10ml aliquots were
analysed directly by western blotting.
Other procedures
Other procedures including assessing mtDNA copy
number by quantitative PCR and the ribonuclease protec-
tion assay (RPA) are described in Supplementary Data.
RESULTS
In silico characterization and mitochondrial localization
of PDE12
The previously identiﬁed 20-PDE protein (19), hereafter
PDE12, contains the domain characteristics of the endo-
nuclease/exonuclease/phosphatase (EEP) family of
proteins (PFAM: PF03372). In order to examine the
genetic divergence of human PDE12 and other human
proteins with the PF03372 domain we built a classiﬁcation
tree (Figure 1A). The analysis revealed that human
PDE12 belongs to a subgroup that contains all established
and putative human deadenylases from the EEP family
(Figure 1A, red) as described by Goldstrohm and
Wickens (16). Human PDE12 shares the same general
domain architecture (Figure 1B) and all key catalytic
residues with other EEP deadenylases (Supplementary
Figure S1). Furthermore, 3D homology modelling of the
PDE12 active site based on the crystal structure of the
poly(A)-speciﬁc ribonuclease CNOT6L (20) indicated a
similar arrangement of the key catalytic residues (Figure
1C and D).
Several computer programmes that scan the N-terminal
region of proteins for the presence of a putative mitochon-
drial targeting sequence (MTS) returned a high probabil-
ity of a MTS in PDE12 (MultiLoc – 98.0%, MitoProt II
– 94%, Predotar – 81%, TargetP – 77% and PSORT –
75%). Moreover, PDE12 is listed in the compendium
of predicted mitochondrial proteins [‘Mitocarta’, (21)]
constructed on the basis of subtractive proteomics
of mitochondria from different tissues, mRNA
co-expression, transcriptional induction during mitochon-
drial proliferation, homology studies and more. Therefore,
PDE12 represented a strong candidate for a mitochondrial
poly(A)-speciﬁc ribonuclease.
Indeed, while our manuscript was in preparation,
Poulsen et al. (22) reported that a His-tagged version of
PDE12 (20-PDE) is localized in the mitochondrial matrix
of HeLa cells (as shown by immunoﬂuorescence, in vitro
import of
35S-labelled recombinant protein and mass
spectrometry of mitochondrial fractions). Transiently
expressed PDE12 with Flag and Strep2 tags also
co-localizes with mitochondria, in HOS cells
(Figure 2A), and endogenous PDE12 co-fractionates
with the well-characterized mitochondrial matrix protein
TFAM and the mitochondrial inner membrane CO2
(Figure 2B). Therefore, it is now established by two
laboratories, using four different techniques, that the
PDE12 protein is present inside the mitochondria of
human cells.
PDE12 has deadenylase activity in vitro
Since PDE12 contains a domain similar to deadenylases
(Figure 1), we tested PDE12 for sequence-speciﬁc nuclease
activity. We generated a point mutation in a putative
magnesium-binding residue by substituting glutamate
at position 351 with alanine (E351A, Figure 1C, cyan).
A point mutation in the analogous residue severely
compromised the activity of other EEP deadenylases
(20,23).
In order to purify the enzymes for biochemical studies, a
Flag- and Strep2-tagged version of the PDE12 wild-type
and the E351A mutant were introduced into HEK293T
cells. The mitochondrial localization of the overexpressed
wild-type PDE12 and the E351A mutant in HEK293T
cells was conﬁrmed by fractionation after induction of
the transgenes for 48h with 50ng/ml of doxycycline.
Both proteins were concentrated in the mitochondrial
fraction (Supplementary Figure S2A). The enzymes were
puriﬁed from mitochondria of HEK293T cells on a
streptavidin-coated matrix (see ‘Material and Methods’
section). SDS–PAGE analysis demonstrated a substantial
enrichment of the tagged proteins (Supplementary Figure
Nucleic Acids Research, 2011,Vol.39, No. 17 7753S2B) and their identities were conﬁrmed by mass spec-
trometry (data not shown).
First, we compared the hydrolytic activity of PDE12
and the E351A mutant using 25nt-long, homopolymeric
RNA (A25) or DNA (dA25) substrates, labelled at their
50-ends. We observed a time-dependent degradation of
the RNA with wild-type, but not E351A mutant,
PDE12; neither protein had any effect on DNA (Figure
3A). The degradation of the 50-end-labelled A25 substrate
resulted in a progressive and sequential appearance of
RNA fragments of lower molecular mass suggesting that
the enzyme hydrolyses RNA in the 30!50 direction. The
addition of a phosphate group at the 30-end of RNA
(substrate A25pCp) completely inhibited RNA degrad-
ation, whereas the analogous RNA substrate with a
30-hydroxyl group (A25pC-OH) was efﬁciently degraded
by the wild-type enzyme (Figure 3A). These results
suggest that PDE12 displays speciﬁcity for RNA 30-ends
containing a free hydroxyl group, and does not possess
50!30 exoribonucleolytic or endoribonucleolytic activity.
Next, we studied the speciﬁcity of PDE12 by comparing
the time-dependent hydrolytic activity of PDE12 on
25nt-long homopolymeric RNA substrates i.e. A25,C 25,
G25 or U25 (Figure 3B). PDE12 preferred A25 and U25 as
substrates, whereas C25 and in particular G25 were poorly
degraded. The speciﬁcity of PDE12 towards poly(A) tails
was further characterized on RNA substrates containing:
(i) a 111nt-long 30-portion of the ND1 human mitochon-
drial gene (30ND1) or (ii) the same 30-portion of ND1
containing a 50nt poly(A) tail (30ND1-A50). Analogous
substrates containing a 111nt-long 30-portion of the
CO2 human mitochondrial gene (30CO2 and 30CO2-A50,
respectively) were also tested. Incubation of recombinant
PDE12, but not the E351A mutant, with the
polyadenylated substrates (30ND1-A50 or 30CO2-A50) for
30min resulted in a size change consistent with the
removal of the poly(A) tail (Figure 3C, compare lanes 4
and 5 or 10 and 11). Of note, the enzyme trimmed both
substrates  6–8nt beyond the poly(A) tail into the body
of the message (Figure 3C, compare lanes 1 and 5 or lanes
7 and 11). Incubation of the enzyme with the poly(A)-less
substrates (30ND1 or 30CO2) resulted in shortening of the
message only by  6–8nt (Figure 3C, compare lanes 1 and
2 or lanes 7 and 8). Taken together, our results (Figure 3)
B A
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Figure 1. Computational analysis of PDE12. (A) The unrooted classiﬁcation tree of human EEP proteins. The sequences of the catalytic domain of
all human proteins of the EEP family (PF03372) were extracted from the Pfam database (see Supplementary Table S1 for details) and aligned using
ClustalW2. Five major subgroups identiﬁed are indicated on the tree: inositol phosphatases (orange), Sphingomyelin phosphodiesterases (grey),
Endo- and exonucleases (green), DNase I-like proteins (blue) and Deadenylases (red). (B) Domain architecture of conﬁrmed and putative human
deadenylases of the EEP family. Functional domains of human proteins of the ‘Deadenylases’ subgroup identiﬁed in (A) are schematically repre-
sented. The position of the EEP domain is represented in each protein by a red box containing the percentage of identity between this domain and
that of PDE12. (C and D) Comparison of the active site structure of PDE12 and other EEP deadenylases. The active site structural motif of PDE12
(C) predicted based on the known crystal structure of the homologous EEP deadenylase CNOT6L (D) using the 3D-Jury algorithm (42) was
modelled using the MODELLER 9v1 software (43).
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ﬁcity for poly(A) tails.
PDE12 transgene expression alters the length of RNA
poly(A) tails in mitochondria
Based on the in vitro data (Figure 3), a high dose of
PDE12 in mitochondria is predicted to shorten poly(A)
tails. In order to determine the effect of PDE12 on
RNA poly(A) tail length of mitochondrial transcripts, re-
combinant PDE12 or the E351A catalytic mutant was ex-
pressed in HEK293T cells. Both proteins were equally
stable in human mitochondria (Figure 4A). In order to
map the exact changes in mt-RNA species, total RNA
was isolated parental HEK293T cells. The length and
sequence of mitochondrial transcripts ND1 and CO2
were analysed after PCR ampliﬁcation, circularization,
reverse transcription and cloning (cRT–PCR). All mito-
chondrial transcripts analyzed preserved the normal
50-end, but in approximately half of the CO2 transcripts
the length of the poly(A) tail was reduced to 40 adenines
or less (48 and 54% for 2 and 4 days of PDE12
overexpression, respectively); all of the ND1 transcripts
had poly(A) tails shorter than 40 adenines after 2 or 4
days of PDE12 overexpression (Figure 4B and
Supplementary Table S2). In  8 and 41% of the CO2
and ND1 transcripts, respectively, the poly(A) tail was
lost completely 4 days after PDE12 induction. Similarly
to the data obtained in vitro (Figure 3C), RNA truncation
of the ND1 and CO2 transcripts by PDE12 did not stop at
the beginning of the poly(A) tract, but continued for up to
8nt, into the 30-termini of the transcripts (Supplementary
Table S2). Some of the truncated ND1 transcripts were
re-adenylated (Supplementary Table S2). Mitochondrial
transcripts of cells overexpressing the E351A catalytic
mutant were indistinguishable from those of control cells
(Figure 4B). These data indicate that PDE12 can degrade
poly(A) tails in human mitochondria.
Removal of poly(A) tails by PDE12 has different
effects on the stability of the various
mitochondrial transcripts
Because there is currently no consensus as to the role
of poly(A) tails in the regulation of mitochondrial
transcript stability, we studied the effects of elevated mito-
chondrial PDE12 expression (deadenylase activity) on the
steady-state levels of all 11 mt-mRNAs by northern blot
analysis. Induction of expression of the PDE12 transgene
resulted in a size reduction of mt-mRNAs consistent with
the removal of the poly(A) from the mitochondrial tran-
scripts (Figure 4C). Deadenylation had transcript-speciﬁc
effects on the stability of individual mt-RNAs. After 4
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Figure 2. Mitochondrial localization of PDE12. (A) The intra-cellular localization of PDE12 by immunoﬂuorescence. The cDNA encoding the
Strep2- and Flag-tagged variant of PDE12 was transiently transfected into HOS cells, the protein product was detected by anti-Flag antibody and
visualized by secondary antibodies conjugated with FITC (green). Mitochondria were stained with MitoTracker Red CMXRos (red). Co-localization
of the green and red signal appears yellow on digitally overlaid images (Merge). (B) Location of PDE12 in subcellular fractions. The HOS cells were
fractionated into cytosol (C, lane 2) and mitochondria (lanes 3–5) as described ‘Material and Methods’ section. The mitochondrial fraction was
treated with 25mg/ml proteinase K in the absence (lane 4) or presence of 1% Triton X-100 (lane 5). ‘T’ denotes the total cell lysate. The protein
fractions were analysed by western blotting using antibodies to endogenous PDE12. The location of PDE12 was compared with that of the following
marker proteins: TFAM (mitochondrial matrix), CO2 (mitochondrial inner membrane) and GAPDH (cytosol).
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and ND2 mRNAs had doubled, ND3 and CytB mRNAs
were one-third higher, whereas the levels of CO1 and
CO2 had halved, compared to those of uninduced cells
(Figure 4D). There was little change in the steady-state
levels of the remaining mt-RNAs: 12S-rRNA,
16S-rRNA, ND4, ND5, ND6, CO3 and ATP6/8
mRNAs were within 15% of the starting level, after 4
days of PDE12 induction (Figure 4D). Overexpression
of the E351A catalytic mutant did not affect the
steady-state level of mt-RNAs (data not shown) consistent
with the retention of poly(A) tails (Figure 4B). Although
PDE12 has no detectable deoxyribonuclease activity
(Figure 3A), it might perturb mtDNA metabolism in
some way. However, mtDNA copy number was un-
changed in cells expressing PDE12 (Figure 4E).
Elevated levels of PDE12 compromise OXPHOS
function
Mitochondrial ATP production and OXPHOS were
analysed in cells-expressing PDE12, or the E351A
mutant, to investigate the consequences of the increased
deadenylase activity on mitochondrial function. Induction
of PDE12, but not E351A, resulted in greater acidiﬁcation
of growth media (Supplementary Figure S3), suggesting
that elevated expression of PDE12 results in increased
dependence on glycolytic as oppose to mitochondrial
ATP production. Furthermore, PDE12 transgene express-
ing cells had a reduced growth rate when cultured in
medium containing 25mM glucose (generation times:
PDE12=1.42±0.06, HEK293T=1.27±0.03 and
E351A=1.30±0.03 days) and the growth impair-
ment was accentuated when the cells’ reliance on mito-
chondrial ATP production was increased by culturing
them in medium containing galactose as the sole carbon
source (generation times: PDE12=2.17±0.13,
HEK293T=1.51±0.04 and E351A=1.48±0.03 days)
(Figure 5A). Overexpression of PDE12 for 4 days




Figure 3. Enzymatic activity of PDE12. (A)3 0!50 exoribonucleolytic
activity of PDE12. 8.5pmoles of PDE12.Strep2.Flag or the E351A
catalytic mutant puriﬁed from human mitochondria were incubated
with 5pmols of radioactively labelled 25nt-long homopolymeric
adenosine RNA (A25), 25nt-long homopolymeric adenosine DNA
(dA25), 25nt-long homopolymeric adenosine RNA labelled on the
30-end with pCp (A25pCp) or 25nt-long homopolymeric adenosine
RNA with cytosine ribonucleotide at the 30-end (A25pC-OH) for the
indicated time. The products were separated on a 10% urea polyacryl-
amide gel and subjected to autoradiography. (B) Sequence speciﬁcity of
PDE12. 8.5pmoles of PDE12.Strep2.Flag or the E351A catalytic
mutant were incubated with 5pmoles of radioactively labelled
25nt-long homopolymeric RNAs consisting of adenine (A25), cytosine
(C25), guanine (G25) or uridine (U25) nucleotides for the indicated time.
The products were separated on a 10% urea polyacrylamide gel and
subjected to autoradiography. (C) Deadenylase activity of PDE12 on
synthetic mt-RNA substrates. About 8.5pmols of PDE12.Strep2.Flag
or the E351A catalytic mutant were incubated with synthetic transcripts
produced by run-off T7 transcription in the presence of radioactive
UTP. The following RNAs were tested: 111nt-long 30-region of the
ND1 ORF (30ND1, lanes 1–3), 111nt-long 30-part of the ND1 ORF
containing a 50nt poly(A) tail (30ND1-A50, lanes 4–6), 111-nt long
30-part of the CO2 ORF (30CO2, lanes 7–9) or 111nt-long 30-part of
the CO2 ORF containing a 50-nt poly(A) tail (30CO2-A50, lanes 10–12).
The products were separated on a 5% urea polyacrylamide gel and
subjected to autoradiography.
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steady-state levels of respiratory chain subunits, as
OXPHOS dysfunction is usually associated with
aberrant assembly or instability of mitochondrial respira-
tory complexes. PDE12 overexpression for 4 or 6 days
markedly reduced the abundance of components of
complex I and subunits of complex IV (Figure 5C).
The observed perturbations in the respiratory
complexes in PDE12 overexpressing cells were additional-
ly reﬂected by cellular oxygen consumption rates
(OCR) that were reduced by  50% of the level of
controls (Figure 5D). The above results suggest that
overexpression of PDE12 causes a severe defect in oxida-
tive metabolism.
PDE12 transgene overexpression inhibits mitochondrial
translation and alters mitoribosomal proﬁle
In order to determine whether the OXPHOS defect in cells
overexpressing PDE12 is a consequence of impaired mito-
chondrial protein synthesis, we labelled the de novo
synthesized mitochondrially encoded subunits of the
electron transport chain with radioactive methionine.
After the inhibition of cytosolic translation, the incorpor-
ation of
35S-Met into mitochondrial proteins was analysed
over a time course of 4 days in HEK293T cells
overexpressing PDE12 or the E351A catalytic mutant
(Figure 6A). Translation of all mitochondrially encoded
respiratory chain subunits was compromised upon the in-






Figure 4. Mitochondrial transcripts in cells overexpressing PDE12. (A) Inducible expression of PDE12 and the E351A catalytic mutant in HEK293T
cells. Western blot illustrating a time course of expression of PDE12.Strep2.Flag or the E351A mutant induced with 50ng/ml doxycycline. The
PDE12 protein was detected using anti-Flag antibody; anti-VDAC-1 antibodies were used as a mitochondrial loading control. (B) Analysis of the
poly(A) tail length of mitochondrial transcripts upon PDE12 induction. Mitochondrial ND1 or CO2 mRNAs were analysed by cRT–PCR and
sequencing as described in ‘Materials and Methods’ section. Each data point represents a single clone analysed for the HEK293T parental cells
(triangle), wild-type PDE12 (circle) and the E351A mutant (square). The length of poly(A) extensions are given on the Y-axis (note that the values
below zero indicate transcripts that were truncated beyond the processing/polyadenylation site). Doxycycline induction times are given on the X-axis.
The horizontal lines represent average lengths of poly(A) tails. (C) Northern blots of mitochondrial transcripts upon overexpression of PDE12. Total
RNA from parental HEK293T cells (H), uninduced cells (0 days) and cells expressing PDE12 for 2 or 4 days (induced with 50ng/ml doxycycline)
from two independent experiments (‘expt. 10 and ‘expt. 20) were analysed by northern blots using probes speciﬁc for all mitochondrial transcripts.
Nuclear-encoded 28S rRNA was used as a loading control. (D) Quantiﬁcation of steady-state levels of mitochondrial transcripts in cells
overexpressing PDE12. The values of the relative RNA levels (mt-RNA/28S rRNA) were obtained by quantifying PhosphorImager scans of
northern blots using ImageQuant software and normalized for the values obtained from uninduced cells. *P<0.05, **P<0.01, ***P<0.001;
n=3, Error bars=1 SD. (E) mtDNA copy number in cells overexpressing PDE12. Comparative Q-PCR of the mitochondrial CytB gene and
single copy nuclear gene (APP) was used with total DNA isolated from cells overexpressing PDE12 for the indicated time. *P<0.05, **P<0.01,
***P<0.001; n=3, Error bars=1SD.
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35S-Met was  15% of those in uninduced cells
(Figure 6B). Overexpression of the E351A mutant did
not have any appreciable effect upon mitochondrial
protein synthesis (Figure 6B). Next, we carried out
gradient sedimentation analyses of cell extracts from
cells overexpressing PDE12 for 4 days and control cells
in order to investigate the integrity of the mitochondrial
ribosome (Figure 6C). In this method, we detected the 28S
(small) and 39S (large) subunits by western blotting of
gradient fractions. We used DAP3/MRPS29 as a marker
for the 28S ribosomal subunit and MRPL3 as a marker
for the 39S subunit. The analyses of sedimentation of
mitoribosomal subunits upon overexpression of PDE12
revealed: (i) deﬁciency of assembled 28S mitoribosomal
subunits as compared to the control and (ii) anomalous
sedimentation of the 39S subunits that was shifted
towards slower migrating species (Figure 6C). These
changes in mitoribosomes were not due to any alteration
in the length of the mitochondrial rRNAs, based on
RNase protection assays of 12S and 16S rRNA
(Supplementary Figure S4A–B). Nor was the steady-state
level or length of 7 mt-tRNAs (Ser-UCN, Leu-UUR, Thr,
Gln, Pro, Lys and Phe) affected by elevated PDE12 ex-
pression (Supplementary Figure S4C–D). However, in the
case of tRNASer-AGY the steady-state level of the
full-length molecule was  60% of the control value after
4 days of PDE12 overexpression and a species of lower
molecular mass was detected. A similar truncated form of
tRNASer-AGY, albeit of much lower abundance, was
observed in control cells (Supplementary Figure S4C).
Mutant tRNA levels considerably >50% are needed to
produce a mitochondrial translation defect (24) and
so the observed inhibition of mitochondrial translation
is most likely attributable to the shortening of the
mt-RNA poly(A) tails, owing to mitochondrial ribosome
instability and/or impaired assembly.
A C
D B
Figure 5. Respiratory chain function upon PDE12 overexpression. (A) Growth of cells overexpressing PDE12 on galactose and glucose media.
Growth curves of parental HEK293 cells or transfectants-expressing PDE12 or the E351A mutant in galactose or glucose (inset) media and induced
for the indicated time. (B) Mitochondrial membrane potential in cells overexpressing PDE12. Mitochondrial membrane potential was assessed by a
quantitative FACS analysis of TMRE intensity. Twenty thousand cells stained with TMRE were analysed for each sample. The percentages of
TMRE intensity were normalized to that of HEK293T cells (=100%). The mtDNA-less HEK293T cells were used as a negative control. **P<0.01,
***P<0.001; two-tailed Student’s t-test; n=3, Error bars=1SD. (C) Steady-state level of the OXPHOS subunits in cells overexpressing PDE12.
Steady-state protein level of subunits of respiratory chain complexes in uninduced control cells or cells overexpressing PDE12 or its catalytic mutant
(E351A) for the indicated time were analysed by western blot. b-Actin was used as a loading control. (D) OCR in cells overexpressing PDE12. OCR
measured in an extracellular ﬂux Seahorse instrument in a quadruplicate population of control uninduced or cells overexpressing PDE12 or its
catalytic mutant (E351A) for 4 days. The wells containing cells were sequentially injected with 20mM 2-DG to inhibit glycolysis, 100nM oligomycin
to inhibit ATP synthase, 1mM FCCP to uncouple the respiratory chain and 200nM rotenone to inhibit complex I.** P<0.01; two-tailed Student’s
t-test; n=3, Error bars=1 SD.
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Figure 6. Mitochondrial translation in cells overexpressing PDE12. (A) Products of mitochondrial translation were labelled with
35S 36methionine
for 15min after expression of PDE12 or the E351A catalytic mutant in HEK293T cells for 2 or 4 days as described in ‘Materials and Methods’
section. Mitochondrial proteins were separated by a 4–12% gradient SDS–PAGE and visualized by autoradiography. To validate equal protein
loading, a small section of the gel was stained with Coomassie. (B) Radiolabelled products of mitochondrial translation as in (A) were quantiﬁed
using ImageQuant software following exposure to a PhosphorImager cassette. ***P<0.001; two-tailed Student’s t-test; n=4, Error bars=1 SD. (C)
Mitochondrial ribosome proﬁle in cells overexpressing PDE12. Cell lysates of HEK293T cells overexpressing PDE12 for 4 days or control cells were
separated on a 10–30% (v:v) isokinetic sucrose gradient. Fractions obtained for control and PDE12 overexpressing cells were analysed by western
blot simultaneously with antibodies to MRPL3 (39S mitoribosomal subunit) and DAP3 (28S mitoribosomal subunit).
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In this work, we show that the EEP family protein PDE12
is the human mitochondrial poly(A)-speciﬁc exoribo-
nuclease. Previously, it has been suggested that human
polynucleotide phosphorylase (PNPase), which has a
phosphorolytic 30!50 exoribonuclease and a poly(A)
polymerase activity, might be responsible for poly(A)
removal in mitochondria (14). However, hPNPase has
been localized to the mitochondrial inter-membrane
space, rather than the matrix where mt-RNA resides,
and a role in processing of mitochondrial transcripts has
been suggested, most likely by indirect means (15,25). As
there is no published data on the presence of other
enzymes from the DEDD of EEP family in human
mitochondria, therefore, PDE12 is the ﬁrst recognized
human mt-RNA deadenylase.
PDE12 as a mitochondrial deadenylase
In the present study, we show that human PDE12
degrades poly(A) tails in vitro and that elevated expression
of PDE12 results in shortening of poly(A) tails of certain
mt-mRNAs in human cultured cells. The previous classi-
ﬁcation of PDE12 (20-PDE) as an EEP-type deadenylase
by Goldstrohm and Wickens (16) was circumstantial;
PDE12 was reported to cleave phosphodiester bonds in
short oligo(A) substrates when the 50-phosphates of each
adenosine are covalently linked between either the 20-o r
30-hydroxyl positions (19). Until recently, the only sug-
gested biological role of PDE12 has been the degradation
of 20–50-linked oligo(A) in the RNase L innate immune
response system and its cellular localization had not
been studied (19). While our manuscript was in prepar-
ation, Poulsen et al. (22) reported the mitochondrial local-
ization of PDE12 and conﬁrmed that recombinant PDE12
produced in Escherichia coli is capable of degrading
30–50-linked RNA. Relatively short RNA substrates were
used containing either (i) a 20-residue generic unstructured
RNA sequence followed by 10 adenosine or cytosine
residues or (ii) an RNA consisting of an 8bp strong
stem–loop structure followed by 10 adenosine residues.
Longer incubation of the recombinant enzyme that
lacked the predicted MTS with all three RNA substrates
resulted in degradation into small fragments of 4–11nt in
size with comparable efﬁciency for all three substrates
(22). In contrast, our studies of the biochemical properties
of PDE12 isolated from human mitochondria show that
PDE12 efﬁciently degrades poly(A) and poly(U), whereas
poly(C) and poly(G) are not preferred substrates. Thus,
PDE12 shares the same preference for poly(A) or poly(U)
substrates as cytoplasmic deadenylases, such as PARN
(26) and POP2 (27). Furthermore, we found that PDE12
isolated from mitochondria exhibits strong speciﬁcity to
poly(A) when relatively long substrates containing a
fragment of endogenous human mitochondrial sequence
(over 100nt of the 30-end of ND1 or CO2) and poly(A)
tails of 50nt (close to the physiological length of the tails
in mt-mRNAs) were used. The enzyme degraded max-
imally eight residues beyond the mRNA-poly(A) tail
boundary. Eight nucleotides was also the maximum
number of bases removed beyond the poly(A) tail of
mt-mRNAs isolated from cells overexpressing PDE12.
Therefore, human PDE12 has characteristics typical of a
number of deadenylases: PARN, CCR4 and CAF1
(23,28). Moreover, as no RNA was truncated beyond
the  8 position, PDE12 is not likely to be responsible
for a general mt-RNA decay, as previously suggested
(22). The discrepancy between the activity of PDE12 on
RNA reported by Poulsen et al. (22) and in the current
study could be owing to: (i) the molar ratio of the enzyme
to RNA (100:1 and 1.7:1, respectively); (ii) the source of
the puriﬁed enzyme (E. coli and human mitochondria, re-
spectively); or (iii) the use of RNA substrates containing
arbitrary rather then natural mitochondrial sequences (see
above).
The poly(U)-degrading property of PDE12 (Figure 3B)
could be of biological signiﬁcance, as the presence of
poly(U) tails in human mt-RNA has been reported
recently (15,29,30). Interestingly, the polyuridinylated
RNA identiﬁed in these cases contained unprocessed
upstream or downstream tRNA genes in addition to a
protein-coding region, and therefore might represent
products of improper processing of the polycistronic pre-
cursor. This suggests that poly(U) tails play a role in the
degradation of mt-RNA, and that PDE12 might contrib-
ute to this process.
PDE12 has been suggested to play a role in
20-50-adenylate catabolism in the RNaseL innate immune
response system. As all components of this pathway are
localized in the cytosol, it is difﬁcult to explain the previ-
ously postulated role of PDE12 in the context of its mito-
chondrial localization. It is possible, however, that an
alternatively localized form of the enzyme exists, which
is involved in the regulation of the RNaseL pathway, as
suggested previously (22). Of note, degradation of both
20-50- and 30-50-linked oligoriboadenylates has been
reported previously for other poly(A)-speciﬁc exoribo-
nucleases (31,32) and might therefore represent a
common property of this class of enzyme.
Mitochondrial poly(A) tails and RNA stability
Polyadenylation plays an important role in regulating
mRNA stability in many systems [see ‘Introduction’
section and ref. (7)]. The role of mitochondrial poly(A)
tails in controlling the stability of mRNA has been
debated. Different approaches have been undertaken to
address this issue in human mitochondria: (i) prevention
of the synthesis of mitochondrial poly(A) by depleting
hmtPAP levels with siRNA (3,4,10) or (ii) trimming
poly(A) tails by targeting the cytosolic poly(A)-speciﬁc
nuclease PARN to mitochondria (12). Independent
studies of hmtPAP gene silencing reached quite different
conclusions as shortening of poly(A) tails did not affect
the stability of the analysed mitochondrial transcripts
(ND3, CO3 and ATP6/8) in one study (3), whereas
others found that the abundance of several mitochondrial
transcripts decreased in response to hmtPAP siRNA
(4,10). It should be stressed, however, that siRNA-
induced downregulation of hmtPAP might not have
been complete and also the existence of a second
polyadenylating enzyme has been postulated (33,34) that
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results of the downregulation of hmtPAP by siRNA. On
the other hand, mitochondrial targeting of PARN com-
pletely removed the 30-poly(A) extensions of mt-RNAs
(12). This had a variable effect on mt-mRNA steady-state
levels, increasing some (ND1, ND2 and ND5) and
decreasing others (CO1, CO2 and ATP6/8), whilst still
others were little changed (ND4/4L and ND3).
Deadenylation of mitochondrial transcripts as a result of
overexpression of PDE12 had a very similar effect on the
steady-state levels of the above transcripts (Figure 4D).
Thus, in both studies removing poly(A) tails from
mt-mRNAs destabilized CO1 and CO2, whereas poly(A)
addition promotes turnover of ND1 and ND2 mRNAs in
human mitochondria, as previously proposed (15,33).
Therefore, there is no universal role of mitochondrial
poly(A) tails in regulation of the RNA stability, and two
classes of poly(A) tails might exist in mitochondria that
have opposite regulatory functions i.e. either stabilization
or destabilization. If stable and degradation inducing
poly(A) tails exist in mitochondria, how do animal
mitochondria differentiate between them? Our data show
that the efﬁciency of degrading of the poly(A) tails by
PDE12 in vitro is different for certain transcripts, e.g.
PDE12 deadenylates ND1 more efﬁciently than CO2
in vitro (Figure 3C), and in cells (Figure 4B). This might
suggest the presence of RNA 30-end cis-regulatory
elements that modulate the deadenylating activity of
PDE12. Perhaps, the structure of the 30-end of the CO2
mRNA partially protects the transcript from
deadenylation, which is particularly intriguing in light of
the fact that the CO2 messenger becomes unstable upon
removal of the poly(A) tail. In summary, our data conﬁrm
a previous suggestion (6,35) that polyadenylation itself is
not sufﬁcient to direct mt-RNA for degradation or to sta-
bilise mitochondrial transcripts and that the regulation of
RNA turnover must depend on additional, yet to be
identiﬁed, factors.
PDE12 as a regulator of mitochondrial translation
Our data show that PDE12 is important for regulating
translation efﬁciency in human mitochondria. The
overexpression of PDE12 resulted in decreased translation
rates for all mitochondrial proteins (Figure 6) despite
the fact that the steady-state levels of the majority of
transcripts were not changed or were up-regulated
(Figure 4D). There was an  50% reduction in the
steady-state levels of only two transcripts—CO1 and
CO2. However, it is unlikely that the down-regulation of
these individual transcripts could have caused the general
inhibition of mitochondrial translation, as published data
indicates that a comparable reduction in the steady-state
levels of two or more human mitochondrial transcripts
does not lead to a global translational defect affecting
all mtDNA-encoded proteins (36). The effect on mito-
chondrial protein synthesis is likely to result from the
removal of poly(A) tails by the exoribonucleolytic
activity of PDE12, rather then from a direct interaction
of the enzyme with the mitochondrial translation machin-
ery (e.g. ribosomes or translation factors) or from an
indirect effect related to a defect in cell growth. This is
supported by the lack of co-sedimentation of PDE12 with
mitoribosomes in sucrose gradient experiments or the lack
of interaction with mitoribosomal proteins in pull-down
experiments (data not shown). Also, conditions that
increase cells’ reliance on mitochondrial ATP production
exacerbated the observed growth phenotype (Figure 5A).
No alterations were observed in the abundance of compo-
nents of complex II (containing only nuclearly encoded
and cytoplasmically translated subunits) nor other cyto-
plasmic proteins (b-actin or GAPDH) suggesting a specif-
ically mitochondrial, rather than cytoplasmic, effect in
cells overexpressing PDE12. Here, again our ﬁndings are
concordant with another study in which mt-mRNA
poly(A) tails were removed by mitochondrial targeting
of the cytosolic deadenylase PARN or coated by
mitochondrially targeted human cytosolic poly(A)-
binding protein, PABPC1 (12), both of which resulted in
marked inhibition of mitochondrial translation.
We excluded the possibility that mitochondrial transla-
tion is inhibited as a consequence of the partial degrad-
ation of mt-rRNAs by PDE12 causing instability or
impeding the assembly of mitoribosomes. This is in agree-
ment with the observation that the 30-termini of
mt-rRNAs normally do not have >1–2nt adenine nucleo-
tides (3) and therefore might not present good substrates
for PDE12 deadenylation. Also, we did not observe a
marked change in the steady-state levels of the majority
of mt-tRNAs analysed. Only tRNA-SerAGY—the
unusual mt-tRNA, which does not fold into cloverleaf
structure (37)—was downregulated by  40% and a
shorter species was observed for this mt-tRNA. This
change is unlikely to account for the dramatic (almost
90%) translation inhibition observed after PDE12 over-
expression. As the truncated product of tRNASer-AGY
was also observed in control cells, it might represent a
relatively stable decay intermediate, which is more
abundant in cells with inhibited mitochondrial translation,
rather then a PDE12 degradation product.
Translation is principally controlled at the initiation
stage (rather than elongation or termination), allowing
for rapid, reversible and spatial regulation of cellular con-
centrations of proteins. Nuclear-encoded eukaryotic tran-
scripts are polyadenylated by the nuclear polyadenylation
machinery. Once the mRNA is transported to the cyto-
plasm, poly(A) not only stabilize RNA, but also promotes
translation initiation. Eukaryotic cytoplasmic initiation
factors recognize the 50-mRNA m
7G cap structure and
the 30-poly(A) tail via poly(A)-binding protein leading to
circularization of the mRNA, which is necessary for trans-
lation initiation (38). The architecture of the mitochon-
drial translation initiation machinery resembles the one
found in bacteria (8), and both bacterial and mitochon-
drial mt-mRNAs lack the 50-end cap structure. However,
mature bacterial messengers do not contain poly(A) tails
as polyadenylation consistently promotes mRNA degrad-
ation in prokaryotes. If, by analogy to Eukaryota, mito-
chondrial poly(A) tails play a role in translation initiation
their removal might primarily affect the stability of the
28S small ribosomal subunit as this subunit binds
mRNA prior to assembly of the 55S mitoribosome (39).
Nucleic Acids Research, 2011,Vol.39, No. 17 7761This would be consistent with the results of our analysis of
mitoribosomal sedimentation on isokinetic density gradi-
ents that shows the steady-state level of the 28S subunit
was notably lower in cells, in which mt-mRNAs were
deadenylated by PDE12 overexpression.
The exonucleolytic activity of PDE12 can extend several
nucleotides beyond the processing/polyadenylation site
(Figures 3C and 4B). This observation brings about an
alternative explanation of how polyadenylation could in-
ﬂuence mitochondrial translation. For 7 of 13 mitochon-
drial ORFs (ND1, ND2 ND3, ND4, CytB, CO3 and
ATP6) removal of several terminal ribonucleotides (e.g.
eight as seen for the ND1 mRNA) would result in trun-
cation of a translation stop codon and at least two
protein-coding triplets. This might be sufﬁcient to inhibit
translation owing to mitoribosome stalling. Studies of
bacterial and eukaryotic systems have identiﬁed several
mechanisms of regulatory stalling of ribosomes that
inhibits protein synthesis (40,41). However, the remaining
six mitochondrial transcripts, ND4L, ND5, ND6, CO1,
CO2 and ATP8, contain 30-UTRs prior to poly(A) exten-
sion that are long enough to ensure the presence of an
entire ORF, even after the removal of 8nt. Nonetheless,
notably lowered steady-state levels of deadenylated
mRNAs-encoding CO1, CO2 and ATP6/8 were
observed in our experiments (Figure 4C) and have been
reported previously by others (4,10,12). Therefore, the
deadenylation-mediated inhibition of mitochondrial trans-
lation could depend on two simultaneous events: removal
of the last 2–3 codons from the 30-ends causing ribosome
stalling and destabilization of mRNAs containing
30-UTRs.
In summary, our study identiﬁes PDE12 as an RNase
that is directly involved in the regulation of mRNA
poly(A) tail lengths in mitochondria. Our results also
underscore the importance of poly(A) tails in modulation
of mitochondrial gene expression and suggest that in
addition to being required for completing the termination
codon of seven mitochondrial ORFs, they also play a role
in mitochondrial protein synthesis.
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